



THOMSON MEDICAL GROUP LIMITED

(Incorporated in the Republic of Singapore)
(Company Registration No. 199908381D)

CLARIFICATION OF ANNOUNCEMENT DATED 17 JANUARY 2024 IN RELATION TO THE GRANT OF FURTHER EXTENSION OF TIME TO RESTORE THE PUBLIC FLOAT

The Board of Directors (the “**Board**”) of Thomson Medical Group Limited (the “**Company**”) refers to the Company’s announcement dated 17 January 2024 in relation to the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) granting the Company a further period of 3 months until 10 April 2024 to explore options to restore its public float as required under Rule 723 of the Listing Manual issued by the SGX-ST (the “**Further Extension**”) and the continued trading of the Company’s shares during this period.

The Board wishes to also inform shareholders of the Company (“**Shareholders**”) that the Further Extension granted by the SGX-ST was based on the further submissions the Company had made to the SGX-ST in its appeal on 12 January 2024.

In summary, the Company had submitted that in conjunction with the restoration of its public float, the Company intends to undertake roadshows after the festive period in February 2024. The roadshows will take into account (i) the Company’s financial results for the 6 months ended 31 December 2023 which will be announced by mid-February 2024 and (ii) the recent acquisition of the FV hospital in Vietnam.

The Company will make such announcements as may be necessary and/or appropriate to update Shareholders on the restoration of its public float, including but not limited to the completion of the restoration of its public float and/or request for a trading halt in the event of any indication of disorderly trading.

In the meantime, trading of the Company’s shares on the Mainboard of the SGX-ST will continue. Shareholders and investors are advised to exercise caution when dealing in the securities of the Company. Shareholders and investors should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

By Order of the Board
THOMSON MEDICAL GROUP LIMITED

Dr Heng Jun Li Melvin
Executive Director and Group CEO
17 January 2024